N4 Pharma PLC (AIM:N4P) Double siRNA Testing Update

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, is pleased to announce successful in vitro testing of Nuvec® loaded with two small interfering RNA (siRNA) probes.

On 14 September 2022, the Company announced a strategic update highlighting its intention to focus its further development work on multiple loaded siRNA on Nuvec®.

The Company has now completed initial in vitro testing of Nuvec® loaded with two generic siRNA probes, GFP (Green Fluorescent protein) and EHMT-2 (Euchromatic Histone Lysine Methyltransferase 2 ) at the same time. The siRNA probes were loaded onto Nuvec® in equal amounts, at a concentration previously shown to be active. Testing demonstrated that both siRNA probes when loaded onto Nuvec® were able to significantly silence their respective targets.

Nigel Theobald, Chief Executive Officer of the Company, commented :

“Showing that Nuvec® loaded with two generic siRNA probes still achieves significant silencing of their respective genes is validation for us to now begin the further work that we announced on 14 September with EGFR and BCl-2 in a PC9 lung cancer model.

“Achieving the initial successful testing of Nuvec ® with the generic GFP and EHMT-2 siRNA will also allow us to commence commercial outreach discussions which will only be further strengthened by the results from the new work we are undertaking.”

The information contained within this announcement is deemed by the Company to constitute inside information as stipulated under the Market Abuse Regulations (EU) No. 596/2014 which has been incorporated into UK law by the European Union (Withdrawal) Act 2018.


N4 Pharma Plc

Nigel Theobald, CEO

Luke Cairns, Executive Director

Linking Shareholders and Executives :Share Talk

If anyone reads this article found it useful, helpful? Then please subscribe www.share-talk.com or follow SHARE TALK on our Twitter page for future updates. Terms of Website Use All information is provided on an as-is basis. Where we allow Bloggers to publish articles on our platform please note these are not our opinions or views and we have no affiliation with the companies mentioned

Weekly Newsletter

Sign up to receive exclusive stock market content in your inbox, once a week.

We don’t spam! Read our privacy policy for more info.